Glaucoma is defined by the progressive degeneration of retinal ganglion cells (RGCs), which ultimately results in permanent vision loss. Reducing Intraocular pressure (IOP) is now the primary therapeutic approach; however, it merely delays the disease's progression and does not provide recovery. However, the present approaches, like eye drops, have low adherence and short-term efficacy, and procedures are susceptible to failure because of wound fibrosis. By encapsulating antifibrotic and IOP-lowering medications in biodegradable nanoparticles (NPs), nanotechnology provides a method that ensures continuous release to protect injured eye cells. Additionally, nanotechnology makes it possible for patients to get therapy in a variety of convenient ways, such as contact lenses, ocular inserts, and eye drops. This review highlights the potential therapeutic applications of nanotechnology for managing glaucoma.
Advancing glaucoma treatment with nanotechnology: a new frontier in ophthalmology.
Roghayyeh Baghban,Mohammad Reza Khalili,A. Zareei,M. Talebnejad
Published 2025 in International journal of pharmaceutics
ABSTRACT
PUBLICATION RECORD
- Publication year
2025
- Venue
International journal of pharmaceutics
- Publication date
2025-10-01
- Fields of study
Medicine, Materials Science, Engineering
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
CITED BY
Showing 1-1 of 1 citing papers · Page 1 of 1